The change in serum TNF-α and sFas among primary liver cancer patients before and after Double intra-arterial infusion of anti-cancer agent
-
摘要: 目的了解原发性肝癌双灌注介入前后血清TNF-α、血清可溶性Fas(sFas)水平的变化,并探讨其临床意义。方法本研究选取75例原发性肝癌患者,其中30例行TACE治疗,45例行TACE联合脾动脉化疗药物灌注治疗,每个病例分别在术前一天、术后二周测定血清TNF-α、sFas,同时对所有病例进行近期疗效判定,另设30例正常对照组。结果肝癌患者的血清TNF-α和sFas的水平均明显高于正常对照组(P<0.01),TACE和双灌注治疗后血清TNF-α和sFas的水平均明显低于治疗前(P<0.01),双灌注治疗组治疗后血清TNF-α和sFas的水平分别低于TACE组治疗后水平(P<0.05),在双灌注组中,近期疗效达有效者血清TNF-α和sFas的水平明显低于无效者(P<0.01)。结论原发性肝癌的双灌注介入治疗后血清TNF-α和sFas的水平明显降低,检测血清TNF-α和sFas的水平可以有助于预后估计。Abstract: Objective To study the clinical significance of change in serum TNF-αand sFas among primary liver cancer patients before and after Double intra-arterial infusion of anti-cancer agent.Methods A total of 75 patients with primary liver cancer were treated with TACE (35 patients) , and TACE Combined with Splenic Arterial Set-catheter Infusion (45 patients) .In addition, 30 patients were included in the study as a normal control group.The patients serum TNFαand sFas were determined before and two weeks after therapy and all the patients were evaluated for the effect of treatment simultaneously.Results Serum TNF-α and sFas levels of primary liver cancer patients were higher than the normal control group (P < 0.01) .Serum TNF-α and sFas levels in patients treated with TACE and Double intra-arterial infusion of anti-cancer agents were lower than the control group (P < 0.01) .The serum TNF-α and sFas levels of patients treated with Double intra-arterial infusion anti-cancer agent were lower than the TACE treatment group (P < 0.05) .Double intra-arterial infusion anti-cancer agent therapy had shown a significant effect on serum TNF-α and sFas's levels of the treated patients than the patients that were not treated (P < 0.01) .Conclusion Patients that were treated with Double intraarterial infusion of anti-cancer agent were shown a significant decrease in serum TNF-α and sFas measurement.Therefore, these parameters can be used to estimate disease prognosis.
-
[1]施海彬.介入放射诊疗策略[M].北京:科学出版社, 2008∶174. [2]王民玉, 张丽.原发性肝癌患者血清TNF-α水平检测及其临床意义[J].实用癌症杂志.2000, 15 (1) ∶31. [3]Pennia D, Van Lan T, Weber RF, et al.Biochemical charac-teriza-tion of the extracellular domain of the75-kilcodalton tumor necrosis factor receptor[J].Bichemistry, 1993, 32 (11) ∶3131. [4]Nagao M, Nakajima Y, Hisanaga M, et al.The alteration of Fas re-ceptor and Ligand system in hepatocellular carcinomas:how do hepa-toma cells escape from the host immune surveillance in vivo[J].Hepatology, 1999, 30 (2) ∶413-421. [5]Jodo S, Kobayashi S, Nakajima Y, et al.Elevated serum levels of-soluble Fas/Apo-1 (CD95) in patients with hepatocellularcarcino-ma[J].Clin Exp Immunol, 1998, 112 (2) ∶166. [6]吴雪平, 王江滨.Fas系统介导的细胞凋亡与肝脏疾病[J].国外医学免疫学分册, 1999, 22 (2) ∶68-71. [7]王凤超, 吕美荣, 钱宛馨, 等.肝细胞癌患者血清可溶性Fas水平检测及其意义[J].蚌埠医学院学报, 2002, 27 (5) ∶461-462. [8]李天晓, 樊青霞, 王瑞林.恶性肿瘤介入治疗学[M].郑州:河南医科大学出版社, 2000∶250. [9]林贵.肝肿瘤的微血管结构和血供[J].中华放射学杂志, 1985, 19 (5) ∶257. [10]王质民.中晚期肝癌介入治疗中应该注意的几个问题[J].介入放射学杂志, 2004, 13 (6) ∶482. [11]郭顺林, 王文辉, 王世杰, 等.肝癌的“双灌注”治疗[J].中国临床医学影像杂志, 2000, 11 (6) ∶412.
本文二维码
计量
- 文章访问数: 220
- HTML全文浏览量: 7
- PDF下载量: 108
- 被引次数: 0